The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Molecular profile of MPN with SVT significantly impacts prognosis
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the significant impact of the molecular profile on the prognosis of patients with myeloproliferative neoplasms (MPN) and splanchnic vein thromboses (SVT). Results suggest that MPN/SVT patients with only JAK2V617F mutation and a low mutant allele burden are at low risk of adverse hematological outcome; however, NGS may identify patients with additional mutations who are at very high long term risk where targeted therapies should be proposed to reduce the risk of transformation. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
